
<http://bio2rdf.org/drugbank:DB00081> a <http://schema.org/Drug> ;
	<http://schema.org/name> "Tositumomab" ;
	<http://schema.org/description> "Murine IgG2a lambda monoclonal antibody against CD20 antigen (2 heavy chains of 451 residues, 2 lambda chains of 220 residues). It is produced in an antibiotic-free culture of mammalian cells. It can be covalently linked to Iodine 131 (a radioactive isotope of iodine)." ;
	<http://schema.org/url> "http://bio2rdf.org/drugbank:DB00081" ;
	<http://schema.org/clinicalPharmacology> "Tositumomab binds to the CD20 antigen, which is predominantly expressed on mature B cells and on >90% of B-cell non-Hodgkin's lympohomas. The antibody leads to selective killing of B-cells." ;
	<http://schema.org/cost> <http://bio2rdf.org/drugbank_resource:304ab26cfa3895f0e69a899b79518ff6> , <http://bio2rdf.org/drugbank_resource:1750aa01a0ce4935de1cc7f1604f5ae5> ;
	<http://schema.org/interactingDrug> "DDI between Tositumomab and Roflumilast - May enhance the immunosuppressive effect of Immunosuppressants." , "DDI between Tositumomab and Dicoumarol - May enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse effects may be increased." , "DDI between Tositumomab and Tofacitinib - Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib." , "DDI between Tositumomab and Belimumab - Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab." , "DDI between Tositumomab and Natalizumab - Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased." , "DDI between Tositumomab and Fondaparinux sodium - May enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse effects may be increased." , "DDI between Tositumomab and Leflunomide - Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased." , "DDI between Trastuzumab and Tositumomab - May enhance the neutropenic effect of Immunosuppressants." , "DDI between Tositumomab and Pimecrolimus - May enhance the adverse/toxic effect of Immunosuppressants." , "DDI between Tositumomab and Sulodexide - May enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse effects may be increased." , "DDI between Tositumomab and Citric Acid - May enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse effects may be increased." , "DDI between Tositumomab and Denosumab - May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased." , "DDI between Tositumomab and Clozapine - Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased." , "DDI between Tositumomab and Warfarin - May enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse effects may be increased." , "DDI between Abciximab and Tositumomab - May enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse effects may be increased." , "DDI between Tositumomab and Edetic Acid - May enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse effects may be increased." , "DDI between Tositumomab and Heparin - May enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse effects may be increased." , "DDI between Tositumomab and Acenocoumarol - May enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse effects may be increased." , "DDI between Tositumomab and Ethyl biscoumacetate - May enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse effects may be increased." , "DDI between Tositumomab and Phenindione - May enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse effects may be increased." , "DDI between Tositumomab and Sipuleucel-T - Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T." , "DDI between Tositumomab and Phenprocoumon - May enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse effects may be increased." , "DDI between Tositumomab and Enoxaparin - May enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse effects may be increased." , "DDI between Tositumomab and Dalteparin - May enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse effects may be increased." , "DDI between Tositumomab and Treprostinil - May enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse effects may be increased." ;
	<http://schema.org/legalStatus> "Approved" ;
	<http://schema.org/mechanismOfAction> "Binds to the CD20 antigen which is found on mature B lymphocytes. The antibody binding appears to induce apoptosis, complement-dependent cytotoxicity and cell death through ionizing radiation." ;
	<http://schema.org/nonProprietaryName> "Ig gamma-1 chain C region" ;
	<http://schema.org/proprietaryName> "Bexxar" ;
	<http://schema.org/identifier> "drugbank:DB00081" ;
	<http://schema.org/sameAs> <http://www.drugbank.ca/drugs/DB00081> , <http://www.rxlist.com/cgi/generic3/bexxar.htm> , <http://www.drugs.com/cdi/iodine-i-131-tositumomab.html> .

<http://bio2rdf.org/drugbank_resource:1750aa01a0ce4935de1cc7f1604f5ae5> a <http://schema.org/DrugCost> ;
	<http://schema.org/costPerUnit> "100.43000030517578125" ;
	<http://schema.org/costCurrency> "USD" ;
	<http://schema.org/drugUnit> "Bexxar 14 mg/ml dosimetric" .

<http://bio2rdf.org/drugbank_resource:304ab26cfa3895f0e69a899b79518ff6> a <http://schema.org/DrugCost> ;
	<http://schema.org/costPerUnit> "180.7700042724609375" ;
	<http://schema.org/costCurrency> "USD" ;
	<http://schema.org/drugUnit> "Bexxar 131 iodine dosimetric" .
